C. Valsuani

FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.

Alfredo Falcone, Chiara Cremolini, Gianluca Masi et al. · Journal of Clinical Oncology · 2013 · 75 citations

Medicine, Oncology, Pharmacology +11

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

Andrea Camerini, C. Puccetti, Sara Donati et al. · BMC Cancer · 2015 · 71 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study

Daniele Campa, Martina Matarazzi, William Greenhalf et al. · International Journal of Cancer · 2018 · 57 citations · Full text

Life Sciences, Genetics, Oncology +17

FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.

Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · Journal of Clinical Oncology · 2013 · 37 citations

Medicine, Pharmacology, Pharmacotherapy +9

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Chiara Cremolini, Federica Marmorino, Fotios Loupakis et al. · BMC Cancer · 2017 · 35 citations · Full text

Medicine, Oncology, Pharmacology +9